TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05269173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flos gossypii flavonoids tablet
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Study: NCT04978974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Program
Description: Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
Study: NCT02832622

Intervention type: DEVICE
Intervention: MPP
Description: MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)

Intervention type: DEVICE
Intervention: BiV/MPP
Description: MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
Study: NCT03460457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Pharmacokinetics/Dynamics Study
Study: NCT00003084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin IV on days 1, 15, and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Description: Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Description: Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral etoposide twice daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV over 1 hour on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IV on days 8, 22, and 36.
Study: NCT01808625

Intervention type: OTHER
Group type: OTHER
Intervention: HYPERBARIC OXYGEN STIMULATION
Description: 30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
Study: NCT03906032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFNA IM Nail
Description: IM nail

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding hip screw
Description: SHS surgical fixation
Study: NCT04633447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously.
Study: NCT02916602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1401
Description: amlodipine, Losartan, Chlorthalidone FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0605
Description: amlodipine, Losartan FDC
Study: NCT01461382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Desks
Description: Treadmill Desk were installed in subjects personal workspace.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Desks
Description: Treadmill desks were installed in subjects personal workspace six months after phase I started.
Study: NCT01450722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bypass surgery, stent placement
Description: bypass surgery, stent placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bypass surgery, stent placement
Description: bypass surgery, stent placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent placement
Description: placement of paclitaxel eluting stent in long superficial femoral artery obstruction
Study: NCT03326960

Intervention type: DRUG
Intervention: Sevoflurane
Description: Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.

Intervention type: DRUG
Intervention: Propofol
Description: Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.

Intervention type: DRUG
Intervention: Desflurane
Description: Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
Study: NCT01533363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled hemorrhoidopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Milligan Morgan
Study: NCT02073916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: antibody-drug conjugate of trastuzumab and emtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dual tyrosine kinase inhibitor (HER2 and EGFR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
Study: NCT02282397

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
Study: NCT02106130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: oral administration, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: oral administration, 3 times/day
Study: NCT00521144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03586752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard program
Description: 60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
Study: NCT03348969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Neoadjuvant Mitomycin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Neoadjuvant Mitomycin C
Study: NCT02574897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic symptom survey
Description: Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blinded Electronic Symptom Survey
Description: Standard of care daily clinician interviews with blinded symptom surveys
Study: NCT03320304

Intervention type: DEVICE
Intervention: Vagal Nerve Simulation (VNS) Therapy
Description: A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
Study: NCT04647396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)
Description: Implementation of the KDIGO bundle for at least 12 hours~1. discontinuation of all nephrotoxic drugs when possible~2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions
Study: NCT04117646

Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: Subjects respond to the translated questionnaire twice at 15 days apart.

Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: Subjects respond to the translated questionnaire twice at 15 days apart.
Study: NCT03346681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
Study: NCT04501640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral adminstration
Study: NCT02173522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate artery embolization (PAE)
Description: Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
Study: NCT03270852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced reality
Description: This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Enhanced reality
Description: Identical rehabilitation without enhanced reality
Study: NCT04339985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 OINTMENT vehicle
Description: ATx201 OINTMENT vehicle
Study: NCT02821741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Twin Stim Plus, 3rd Edition
Description: Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
Study: NCT01478009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: Korean red ginseng(3.0g/day) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3.0g/day) for 12 weeks
Study: NCT02821741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Twin Stim Plus, 3rd Edition
Description: Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc Pathway System
Description: Device used to apply Thermal stimulation to both arms.
Study: NCT00464451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral hydrate
Description: Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Study: NCT04141631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)
Description: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
Study: NCT02821741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medoc Pathway System
Description: Device used to apply Thermal stimulation to both arms.
Study: NCT04470544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: At Investigator discretion
Study: NCT02544113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Treatment with thymoglobulin and delayed CNI post OLT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal transplant immunosuppression
Study: NCT02262364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APS
Description: See above
Study: NCT04066400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Dietary Counselling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Intervention
Description: Dietary Counselling
Study: NCT00572351

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Wine
Description: 8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Wine
Description: 8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
Study: NCT03218826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3Kbeta Inhibitor AZD8186
Description: Given PO
Study: NCT02666378

Intervention type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: Subjects will be recruited for observational cardiac magnetic resonance imaging.

Intervention type: OTHER
Intervention: Echocardiogram (ECHO)
Description: Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
Study: NCT01928966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pumpkin Seeds
Description: Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pumpkin Seeds
Description: Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
Study: NCT03830190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's disease nurse specialist care
Description: Specialized nursing care provided by a Parkinson's disease nurse specialist
Study: NCT00264979

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Simultaneous surgery
Description: Simultaneous surgery of colorectal cancer and synchronous liver metastases

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequential surgery
Description: Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
Study: NCT03642938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
Study: NCT03498378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (IV on days 1 and 15 of 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min.
Study: NCT03642938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Control group will perform 30 minutes of quiet rest.
Study: NCT01934803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03035890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-Therapeutic Agent
Description: Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity.
Study: NCT00757913

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: n-3 enriched nutrition
Study: NCT01502618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: N/A. Protocol is the focus group
Study: NCT06072222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilator
Description: ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator
Description: ventilator
Study: NCT00049036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV